

Claims

1. A drug delivery system to a posterior segment of an eye characterized in that fine particles containing a drug are subconjunctivally administered.

2. A subconjunctival injection which comprises fine particles containing a drug and enables the drug to deliver to a posterior segment of an eye.

3. The drug delivery system as claimed in claim 1 and the subconjunctival injection as claimed in claim 2, wherein an average particle diameter of the fine particles is 50 nm to 150 μ m.

4. The drug delivery system as claimed in claim 1 and the subconjunctival injection as claimed in claim 2, wherein the fine particles are made of a biodegradable or biosoluble polymer.

5. The drug delivery system as claimed in claim 1 and the subconjunctival injection as claimed in claim 2, wherein the posterior segment of the eye is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

6. The drug delivery system as claimed in claim 1 and the subconjunctival injection as claimed in claim 2, wherein the drug is a drug for treatment or prevention of a disease of a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

7. The drug delivery system as claimed in claim 1 and the subconjunctival injection as claimed in claim 2, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrobial or an antifungal agent.

8. A method of treating and/or preventing a disease of a posterior segment of an eye comprising administering subconjunctivally to a patient an effective amount for treatment of an injection comprising fine particles containing a drug.

9. The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein an average particle diameter of the fine particles is 50 nm to 150 μ m.

10. The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a biodegradable or biosoluble polymer.

11. The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein the posterior segment of the eye is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

12. The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein the drug is an anti-inflammatory, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrobial or an antifungal agent.